I rate Bio-Rad (BIO) with a buy rating. I start by mentioning that the low growth perspective is the negative aspect. For 2025, the company expects a 0.25% growth rate for its revenues, which might ...
Bio-Rad's Q3 saw the company book $653 million in revenue, which was very modestly (0.5%) higher on a year-over-year basis. Net income not according to generally accepted accounting principles (GAAP) ...
Did you analyze how Bio-Rad Laboratories (BIO) fared in its international operations for the quarter ending December 2024? Given the widespread global presence of this maker of instruments used in ...
We recently published a list of Billionaire Mason Hawkins’ 10 Small-Cap Stocks with Huge Upside Potential. In this article, we are going to take a look at where Bio-Rad Laboratories, Inc. (NYSE:BIO) ...
Bio-Rad Laboratories, Inc. BIO is well-poised to grow in the upcoming quarters, courtesy of its strong traction in the QX600 Droplet Digital PCR (ddPCR) platform. Demand for its quality control and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results